Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Review

Abstract

Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects. Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.

Keywords

Cyclooxygenase inhibitor NSAID Coxibs Cardiovascular adverse event Hypertension Heart failure Prostacyclin Thromboxane 

References

  1. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J (2002) Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 25:537–544CrossRefPubMedGoogle Scholar
  2. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomised controlled trial. JAMA 289:2819–2826PubMedGoogle Scholar
  3. Altman R, Luciardi HL, Muntaner J, Del Rio F, Berman SG, Lopez R, Gonzalez C (2002) Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 106:191–195CrossRefPubMedGoogle Scholar
  4. Andreassi MG, Botto N (2003) DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc Med 13:270–275CrossRefPubMedGoogle Scholar
  5. Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86Google Scholar
  6. Arvanitis DA, Flouris GA, Spandidos DA (2005) Genomic rearrangements on VCAM1, SELE, APEG1and AIF1 loci in atherosclerosis. J Cell Mol Med 9:153–159PubMedGoogle Scholar
  7. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Guhring H (2003) Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur J Neurosci 17:597–604CrossRefPubMedGoogle Scholar
  8. Aw TJ, Haas SJ, Liew D, Krum H (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165:490–496CrossRefPubMedGoogle Scholar
  9. Barden J, Edwards JE, McQuay HJ, Moore RA (2003) Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesiol 3:1CrossRefPubMedGoogle Scholar
  10. Barton SF, Langeland FF, Snabes MC, LeComte D, Kuss ME, Dhadda SS, Hubbard RC (2002) Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 97:306–314CrossRefPubMedGoogle Scholar
  11. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, Kunos G (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110:1996–2002CrossRefPubMedGoogle Scholar
  12. Bernatsky S, Hudson M, Suissa S (2005) Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford, England) 44:677–680Google Scholar
  13. Berndt G, Grosser N, Hoogstraate J, Schroder H (2005) AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci 25:229–235PubMedGoogle Scholar
  14. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, Dagenais GR (2004) Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomised placebo-controlled study. Circulation 110:934–939CrossRefPubMedGoogle Scholar
  15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520–1528, 1522 p following 1528CrossRefPubMedGoogle Scholar
  16. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J (2002) Use of ramipril in preventing stroke: double blind randomised trial. BMJ 324:699–702CrossRefPubMedGoogle Scholar
  17. Bremner HR, Freywald T, O’Brodovich HM, Otulakowski G (2002) Promoter analysis of the gene encoding the beta-subunit of the rat amiloride-sensitive epithelial sodium channel. Am J Physiol Lung Cell Mol Physiol 282:L124–L134PubMedGoogle Scholar
  18. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102PubMedGoogle Scholar
  19. Brinker A, Goldkind L, Bonnel R, Beitz J (2004) Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 21:479–484CrossRefPubMedGoogle Scholar
  20. Brochier ML (1993) Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J 14:951–957PubMedGoogle Scholar
  21. Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, Mugge A (2003) Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens 21:1663–1667CrossRefPubMedGoogle Scholar
  22. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW (2005a) Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 112:110–116CrossRefPubMedGoogle Scholar
  23. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW (2005b) Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 45:69–74PubMedGoogle Scholar
  24. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, Ehrich E, Mukhopadhyay S, Daniels B (2000) Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomised, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 43:978–987CrossRefPubMedGoogle Scholar
  25. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P (2004) Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109:1468–1471CrossRefPubMedGoogle Scholar
  26. Cataldo G, Heiman F, Lavezzari M, Marubini E (1998) Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: results of a combined analysis. Coron Artery Dis 9:217–222PubMedGoogle Scholar
  27. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ (2001) Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 167:2831–2838PubMedGoogle Scholar
  28. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O’Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I et al (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551–560PubMedGoogle Scholar
  29. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F (2003) Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107:405–409CrossRefPubMedGoogle Scholar
  30. Cheng HF, Harris RC (2004) Cyclooxygenases, the kidney, and hypertension. Hypertension 43:525–530CrossRefPubMedGoogle Scholar
  31. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539–541CrossRefPubMedMathSciNetGoogle Scholar
  32. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN (2004) Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomised human trial. Proc Natl Acad Sci USA 101:15178–15183CrossRefPubMedGoogle Scholar
  33. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A (2004) A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291:2221–2228CrossRefPubMedGoogle Scholar
  34. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, Zhao PL, Rodgers DB, McCormick CL, Lee M, Lines CR, Gertz BJ (2002) A multinational randomised, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 3:10CrossRefPubMedGoogle Scholar
  35. Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, DuBois NB, Ashton AW, Latif F, Jorde UP, Ware JA, LeJemtel TH (2005) Endothelial cell activation in patients with decompensated heart failure. Circulation 111:58–62CrossRefPubMedGoogle Scholar
  36. Committee FA (2001) Rockville, Md: Food and Drug Administration, Cardiovascular Safety Review of Rofecoxib. Available at: http://wwwfdagov/ohrms/dockets/ac/01/briefing/3677b2_06_cardiopdf
  37. Connolly E, Bouchier-Hayes DJ, Kaye E, Leahy A, Fitzgerald D, Belton O (2002) Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther 300:393–398CrossRefPubMedGoogle Scholar
  38. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, Kouroedov A, Delli Gatti C, Joch H, Volpe M, Luscher TF (2003) High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 107:1017–1023CrossRefPubMedGoogle Scholar
  39. Davidge ST (2001) Prostaglandin H synthase and vascular function. Circ Res 89:650–660PubMedGoogle Scholar
  40. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E (2000) A randomised trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 160:1781–1787CrossRefPubMedGoogle Scholar
  41. Delgado RM 3rd, Nawar MA, Zewail AM, Kar B, Vaughn WK, Wu KK, Aleksic N, Sivasubramanian N, McKay K, Mann DL, Willerson JT (2004) Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 109:1428–1433CrossRefPubMedGoogle Scholar
  42. Deng YM, Wu BJ, Witting PK, Stocker R (2004) Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 110:1855–1860CrossRefPubMedGoogle Scholar
  43. Derry S, Loke YK (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321:1183–1187CrossRefPubMedGoogle Scholar
  44. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E, Lawson JA, FitzGerald GA (2005) Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111:334–342CrossRefPubMedGoogle Scholar
  45. Ehrich EW, Bolognese JA, Watson DJ, Kong SX (2001) Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. Am J Manag Care 7:609–616PubMedGoogle Scholar
  46. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364:675–684CrossRefPubMedGoogle Scholar
  47. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH (2002) Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 162:265–270CrossRefPubMedGoogle Scholar
  48. Fierro IM, Kutok JL, Serhan CN (2002) Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 300:385–392CrossRefPubMedGoogle Scholar
  49. FitzGerald GA (2003) COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2:879–890CrossRefPubMedGoogle Scholar
  50. Fornaro G, Rossi P, Mantica PG, Caccia ME, Aralda D, Lavezzari M, Pamparana F, Milanesi G (1993) Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomised, placebo-controlled, double-blind study. Circulation 87:162–164PubMedGoogle Scholar
  51. Fredy J, Diggins DA Jr, Morrill GB (2005) Blood pressure in native americans switched from celecoxib to rofecoxib. Ann Pharmacother 39:797–802CrossRefPubMedGoogle Scholar
  52. Friedman PL, Brown EJ Jr, Gunther S, Alexander RW, Barry WH, Mudge GH Jr, Grossman W (1981) Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease. N Engl J Med 305:1171–1175PubMedCrossRefGoogle Scholar
  53. Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, Mannucci PM, Mininni N, Prando MD, Tubaro M, Vernocchi A, Vecchio C (2004) N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 110:128–134CrossRefPubMedGoogle Scholar
  54. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A (2004) Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109:3000–3006CrossRefPubMedGoogle Scholar
  55. Gardner RS, Chong V, Morton I, McDonagh TA (2005) N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur J Heart Fail 7:253–260CrossRefPubMedGoogle Scholar
  56. Gertz BJ, Krupa D, Bolognese JA, Sperling RS, Reicin A (2002) A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin 18:82–91CrossRefPubMedGoogle Scholar
  57. Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Hettiarachchi R, Marras E, Stefani PM, Girolami A, Buller HR (1999) Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 81:715–722PubMedGoogle Scholar
  58. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB (2004) Acute myocardial hypoxia increases BNP gene expression. Faseb J 18:1928–1930PubMedGoogle Scholar
  59. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475–481PubMedGoogle Scholar
  60. Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, Pohle T, Seidman DS, Schroder H (2003) Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun 308:956–960CrossRefPubMedGoogle Scholar
  61. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–1762CrossRefPubMedGoogle Scholar
  62. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94:2504–2510PubMedCrossRefGoogle Scholar
  63. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective randomised Cumulative Survival (COPERNICUS) trial. Circulation 110:1780–1786CrossRefPubMedGoogle Scholar
  64. Hartner A, Cordasic N, Goppelt-Struebe M, Veelken R, Hilgers KF (2003) Role of macula densa cyclooxygenase-2 in renovascular hypertension. Am J Physiol Renal Physiol 284:F498–502PubMedGoogle Scholar
  65. Hatzistamou J, Kiaris H, Ergazaki M, Spandidos DA (1996) Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 225:186–190CrossRefPubMedGoogle Scholar
  66. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E (2000) Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomised, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 43:370–377CrossRefPubMedGoogle Scholar
  67. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A (1998) NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 158:1108–1112CrossRefPubMedGoogle Scholar
  68. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110:3206–3212CrossRefPubMedGoogle Scholar
  69. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F (2003) Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108:2308–2311CrossRefPubMedGoogle Scholar
  70. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366CrossRefPubMedGoogle Scholar
  71. Hippisley-Cox J, Coupland C, Logan R (2005) Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331:1310–1316CrossRefPubMedGoogle Scholar
  72. Hocherl K, Dreher F, Kurtz A, Bucher M (2002a) Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension 40:947–953CrossRefPubMedGoogle Scholar
  73. Hocherl K, Endemann D, Kammerl MC, Grobecker HF, Kurtz A (2002b) Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol 136:1117–1126CrossRefPubMedGoogle Scholar
  74. Holt S, Fowler CJ (2003) Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH. Naunyn Schmiedebergs Arch Pharmacol 367:237–244CrossRefPubMedGoogle Scholar
  75. Hou CC, Hung SL, Kao SH, Chen TH, Lee HM (2005) Celecoxib induces heme-oxygenase expression in glomerular mesangial cells. Ann N Y Acad Sci 1042:235–245CrossRefPubMedGoogle Scholar
  76. Hudson M, Richard H, Pilote L (2005) Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 330:1370CrossRefPubMedGoogle Scholar
  77. Ishikawa K, Sugawara D, Wang X, Suzuki K, Itabe H, Maruyama Y, Lusis AJ (2001) Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res 88:506–512PubMedGoogle Scholar
  78. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108:275–281CrossRefPubMedGoogle Scholar
  79. Jiang H, Weyrich AS, Zimmerman GA, McIntyre TM (2004) Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E2 production that modulate motility. J Biol Chem 279:55905–55913CrossRefPubMedGoogle Scholar
  80. Jick SS (2000) The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy 20:741–744CrossRefPubMedGoogle Scholar
  81. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165:978–984CrossRefPubMedGoogle Scholar
  82. Johnson AG (1998) NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging 12:17–27CrossRefPubMedGoogle Scholar
  83. Jones SC (2005) Relative thromboembolic risks associated with cOX-2 inhibitors. Ann Pharmacother 39:1249–1259CrossRefPubMedGoogle Scholar
  84. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029CrossRefPubMedGoogle Scholar
  85. Kato M, Nishida S, Kitasato H, Sakata N, Kawai S (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 53:1679–1685CrossRefPubMedGoogle Scholar
  86. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL (2005) Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142:157–164PubMedGoogle Scholar
  87. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293:1609–1616CrossRefPubMedGoogle Scholar
  88. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R (2005) N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352:666–675CrossRefPubMedGoogle Scholar
  89. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J (1999) A randomised trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117:776–783CrossRefPubMedGoogle Scholar
  90. Layton D, Hughes K, Harris S, Shakir SA (2003) Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford, England) 42:1354–1364Google Scholar
  91. Lee C, Hunsche E, Balshaw R, Kong SX, Schnitzer TJ (2005) Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. Arthritis Rheum 53:510–518CrossRefPubMedGoogle Scholar
  92. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2:612–619CrossRefPubMedGoogle Scholar
  93. Liou JY, Shyue SK, Tsai MJ, Chung CL, Chu KY, Wu KK (2000) Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells. J Biol Chem 275:15314–15320CrossRefPubMedGoogle Scholar
  94. Liu X, Wei J, Peng DH, Layne MD, Yet SF (2005) Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice. Diabetes 54:778–784PubMedGoogle Scholar
  95. Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P (2005) Plasma cystatin-C and development of coronary heart disease: The PRIME Study. AtherosclerosisGoogle Scholar
  96. MacMahon S (2000) Blood pressure and the risk of cardiovascular disease. N Engl J Med 342:50–52CrossRefPubMedGoogle Scholar
  97. Malan TP Jr, Gordon S, Hubbard R, Snabes M (2005) The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery. Anesth Analg 100:454–460CrossRefPubMedGoogle Scholar
  98. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A (2003) Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 163:481–486CrossRefPubMedGoogle Scholar
  99. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363:1751–1756CrossRefPubMedGoogle Scholar
  100. Mannucci L, Maderna P, Colli S, Lavezzari M, Sirtori CR, Tremoli E (1987) Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. Thromb Res 48:417–426CrossRefPubMedGoogle Scholar
  101. Marra DE, Simoncini T, Liao JK (2000) Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation 102:2124–2130PubMedGoogle Scholar
  102. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272–277CrossRefPubMedGoogle Scholar
  103. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, Weksler BB, Sanborn TA, Bergman G, Bush HL Jr (1997) Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 100:2182–2188PubMedGoogle Scholar
  104. McMahon B, Mitchell S, Brady HR, Godson C (2001) Lipoxins: revelations on resolution. Trends Pharmacol Sci 22:391–395CrossRefPubMedGoogle Scholar
  105. Meeking DR, Browne DL, Allard S, Munday J, Chowienczyck PJ, Shaw KM, Cummings MH (2000) Effects of cyclo-oxygenase inhibition on vasodilatory response to acetylcholine in patients with type 1 diabetes and nondiabetic subjects. Diabetes Care 23:1840–1843PubMedGoogle Scholar
  106. Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell’Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella MA, Dzau VJ (2002) Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 105:602–607CrossRefPubMedGoogle Scholar
  107. Moore RA, Derry S, Makinson GT, McQuay HJ (2005) Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 7:R644–R665CrossRefPubMedGoogle Scholar
  108. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–959CrossRefPubMedGoogle Scholar
  109. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Villela CG, Fierro IM (2005) Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol 289:C557–C563CrossRefPubMedGoogle Scholar
  110. NDA21-389 (2005) Phase II/III trials with etoricoxib. Available at: http://wwwfdagov/ohrms/dockets/ac/05/briefing/2005-4090B1_31_AA-FDA-Tab-Tpdf
  111. Niederberger E, Tegeder I, Schafer C, Seegel M, Grosch S, Geisslinger G (2003) Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. J Pharmacol Exp Ther 304:1153–1160CrossRefPubMedGoogle Scholar
  112. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081–1091CrossRefPubMedGoogle Scholar
  113. Ogasawara A, Arakawa T, Kaneda T, Takuma T, Sato T, Kaneko H, Kumegawa M, Hakeda Y (2001) Fluid shear stress-induced cyclooxygenase-2 expression is mediated by C/EBP beta, cAMP-response element-binding protein, and AP-1 in osteoblastic MC3T3-E1 cells. J Biol Chem 276:7048–7054CrossRefPubMedGoogle Scholar
  114. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano DT (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125:1481–1492CrossRefPubMedGoogle Scholar
  115. Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 160:777–784CrossRefPubMedGoogle Scholar
  116. Pattaragarn A, Alon US (2003) Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. Pediatr Nephrol 18:1073–1076CrossRefPubMedGoogle Scholar
  117. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW (2004) 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 200:69–78CrossRefPubMedGoogle Scholar
  118. Pope JE, Anderson JJ, Felson DT (1993) A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153:477–484CrossRefPubMedGoogle Scholar
  119. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA (2001) Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98:3358–3363CrossRefPubMedGoogle Scholar
  120. Radack KL, Deck CC, Bloomfield SS (1987) Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomised, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med 107:628–635PubMedGoogle Scholar
  121. Rahme E, Pilote L, LeLorier J (2002) Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 162:1111–1115CrossRefPubMedGoogle Scholar
  122. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360:1071–1073CrossRefPubMedGoogle Scholar
  123. Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J (2003) COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Pharmacoepidemiol Drug Saf 12:67–70CrossRefPubMedGoogle Scholar
  124. Reis ED, Roque M, Dansky H, Fallon JT, Badimon JJ, Cordon-Cardo C, Shiff SJ, Fisher EA (2000) Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 97:12764–12769CrossRefPubMedGoogle Scholar
  125. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97:1921–1929PubMedGoogle Scholar
  126. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558–566PubMedGoogle Scholar
  127. Rofecoxib B (2004) Advisory Committee Background Information BG1231. available at: http://www.fdagov/ohrms/dockets/ac/05/briefing/2005-4090B1_02_MERCK-Vioxxpdf
  128. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M (1999) Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66:76–84CrossRefPubMedGoogle Scholar
  129. Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, Sperling R, Daniels B (2000) Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med 9:1124–1134CrossRefPubMedGoogle Scholar
  130. Schildknecht S, Bachschmid M, Baumann A, Ullrich V (2004) COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin-exposed vascular smooth muscle cells. FASEB J 18:757–759PubMedGoogle Scholar
  131. Schlienger RG, Jick H, Meier CR (2002) Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 54:327–332CrossRefPubMedGoogle Scholar
  132. Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, Bolognese J, Seidenberg B, Ehrich EW (1999) The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 21:1688–1702CrossRefPubMedGoogle Scholar
  133. Schnitzer TJ, Kong SX, Mitchell JH, Mavros P, Watson DJ, Pellissier JM, Straus WL (2003) An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clin Ther 25:3162–3172CrossRefPubMedGoogle Scholar
  134. Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP (2005) Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheumatol 32:1093–1105PubMedGoogle Scholar
  135. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K (2002) Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 72:50–61CrossRefPubMedGoogle Scholar
  136. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247–1255CrossRefPubMedGoogle Scholar
  137. Smith LH, Boutaud O, Breyer M, Morrow JD, Oates JA, Vaughan DE (2002) Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arterioscler Thromb Vasc Biol 22:983–988CrossRefPubMedGoogle Scholar
  138. Solomon DH, Glynn RJ, Levin R, Avorn J (2002) Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 162:1099–1104CrossRefPubMedGoogle Scholar
  139. Solomon DH, Schneeweiss S, Levin R, Avorn J (2004a) Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44:140–145CrossRefPubMedGoogle Scholar
  140. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J (2004b) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109:2068–2073CrossRefPubMedGoogle Scholar
  141. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080CrossRefPubMedGoogle Scholar
  142. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG (2005) The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 165:161–168CrossRefPubMedGoogle Scholar
  143. Spandidos DA, Ergazaki M, Arvanitis D, Kiaris H (1996) Microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 220:137–140CrossRefPubMedGoogle Scholar
  144. Staessen JA, Wang JG, Thijs L (2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358:1305–1315CrossRefPubMedGoogle Scholar
  145. Steffel J, Hermann M, Greutert H, Gay S, Luscher TF, Ruschitzka F, Tanner FC (2005) Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 111:1685–1689CrossRefPubMedGoogle Scholar
  146. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A (1997) Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 29:274–279PubMedGoogle Scholar
  147. Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G (1999) Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther 65:533–544CrossRefPubMedGoogle Scholar
  148. Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J 15:2057–2072CrossRefPubMedGoogle Scholar
  149. Topper JN, Cai J, Falb D, Gimbrone MA Jr (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93:10417–10422CrossRefPubMedGoogle Scholar
  150. Tuleja E, Mejza F, Cmiel A, Szczeklik A (2003) Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. Arterioscler Thromb Vasc Biol 23:1111–1115CrossRefPubMedGoogle Scholar
  151. Umenishi F, Verkman AS (1998) Isolation and functional analysis of alternative promoters in the human aquaporin-4 water channel gene. Genomics 50:373–377CrossRefPubMedGoogle Scholar
  152. Van den Ouweland FA, Gribnau FW, Meyboom RH (1988) Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly. Age Ageing 17:8–16PubMedGoogle Scholar
  153. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40:1109–1120PubMedGoogle Scholar
  154. Van Kraaij DJ, Hovestad-Witterland AH, de Metz M, Vollaard EJ (2002) A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers. Br J Clin Pharmacol 53:644–647CrossRefPubMedGoogle Scholar
  155. Von der Weid PY, Hollenberg MD, Fiorucci S, Wallace JL (2004) Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation 110:1320–1325CrossRefPubMedGoogle Scholar
  156. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP (2004) Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 177:235–243CrossRefPubMedGoogle Scholar
  157. Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, Koki AT, Smith ME, Keller BT, Topol EJ, Lincoff AM, Penn MS (2005) Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 45:61–67CrossRefPubMedGoogle Scholar
  158. Watson DJ, Rhodes T, Cai B, Guess HA (2002) Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162:1105–1110CrossRefPubMedGoogle Scholar
  159. Weideman RA, Kelly KC, Kelley CL, Cryer B (2002) COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs. Am J Manag Care 8:869–877PubMedGoogle Scholar
  160. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007CrossRefPubMedGoogle Scholar
  161. Whelton A (2002) COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. J Hypertens 20[Suppl 6]:S31–S35Google Scholar
  162. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM (2001) Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomised, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8:85–95CrossRefPubMedGoogle Scholar
  163. Whelton A, White WB, Bello AE, Puma JA, Fort JG (2002) Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90:959–963CrossRefPubMedGoogle Scholar
  164. White WB, Strand V, Roberts R, Whelton A (2004) Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 11:244–250CrossRefPubMedGoogle Scholar
  165. Wolfe F, Zhao S, Pettitt D (2004) Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 31:1143–1151PubMedGoogle Scholar
  166. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A (1998) Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 98:100–103PubMedGoogle Scholar
  167. Wong E, Huang JQ, Tagari P, Riendeau D (2001) Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis 157:393–402CrossRefPubMedGoogle Scholar
  168. Wu G, Mannam AP, Wu J, Kirbis S, Shie JL, Chen C, Laham RJ, Sellke FW, Li J (2003) Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol 285:H2420–H2429PubMedGoogle Scholar
  169. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, Kim SH, Oh BH, Lee MM, Park YB, Walsh K (2004) Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110:301–308CrossRefPubMedGoogle Scholar
  170. Yasui M, Zelenin SM, Celsi G, Aperia A (1997) Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Am J Physiol 272:F443–F450PubMedGoogle Scholar
  171. Zhang M, Zhang BH, Chen L, An W (2002) Overexpression of heme oxygenase-1 protects smooth muscle cells against oxidative injury and inhibits cell proliferation. Cell Res 12:123–132CrossRefPubMedGoogle Scholar
  172. Zhang Z, Vezza R, Plappert T, McNamara P, Lawson JA, Austin S, Pratico D, Sutton MS, FitzGerald GA (2003) COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res 92:1153–1161CrossRefPubMedGoogle Scholar
  173. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC (2002a) Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care 8:S414–S427PubMedGoogle Scholar
  174. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC (2002b) Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care 8:S401–S413PubMedGoogle Scholar
  175. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (2002) Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94:1745–1757PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Pharmazentrum Frankfurt/ZAFES, Institut für Klinische PharmakologieKlinikum der Johann Wolfgang Goethe-Universität FrankfurtFrankfurt am MainGermany

Personalised recommendations